Abstract
We evaluated the expression of MAGE-3 protein in gastric carcinoma by immunohistochemistry, and compared the frequency between primary lesions and metastatic lymph nodes. Primary lesions and metastatic lymph nodes of 38 cases of gastric carcinoma were analyzed using anti-MAGE-3 monoclonal antibody. Expression of MAGE-3 protein was detected in 17 (45%) primary lesions and 12 (32%) metastatic lymph nodes of 38 cases. In 70% of positive cases of primary lesions, the percentage of stained cells with MAGE-3 decreased in metastatic lymph nodes. The heterogeneous expression of MAGE-3 should be considered when we perform antigen specific immunotherapy for patients with gastric carcinoma.
| Original language | English |
|---|---|
| Pages (from-to) | 975-977 |
| Number of pages | 3 |
| Journal | Oncology reports |
| Volume | 6 |
| Issue number | 5 |
| Publication status | Published - Jan 1 1999 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
The heterogeneous expression of MAGE-3 protein : difference between primary lesions and metastatic lymph nodes in gastric carcinoma. / Sadanaga, N.; Nagashima, H.; Tahara, K.; Yoshikawa, Y.; Mori, Masaki.
In: Oncology reports, Vol. 6, No. 5, 01.01.1999, p. 975-977.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The heterogeneous expression of MAGE-3 protein
T2 - difference between primary lesions and metastatic lymph nodes in gastric carcinoma.
AU - Sadanaga, N.
AU - Nagashima, H.
AU - Tahara, K.
AU - Yoshikawa, Y.
AU - Mori, Masaki
PY - 1999/1/1
Y1 - 1999/1/1
N2 - We evaluated the expression of MAGE-3 protein in gastric carcinoma by immunohistochemistry, and compared the frequency between primary lesions and metastatic lymph nodes. Primary lesions and metastatic lymph nodes of 38 cases of gastric carcinoma were analyzed using anti-MAGE-3 monoclonal antibody. Expression of MAGE-3 protein was detected in 17 (45%) primary lesions and 12 (32%) metastatic lymph nodes of 38 cases. In 70% of positive cases of primary lesions, the percentage of stained cells with MAGE-3 decreased in metastatic lymph nodes. The heterogeneous expression of MAGE-3 should be considered when we perform antigen specific immunotherapy for patients with gastric carcinoma.
AB - We evaluated the expression of MAGE-3 protein in gastric carcinoma by immunohistochemistry, and compared the frequency between primary lesions and metastatic lymph nodes. Primary lesions and metastatic lymph nodes of 38 cases of gastric carcinoma were analyzed using anti-MAGE-3 monoclonal antibody. Expression of MAGE-3 protein was detected in 17 (45%) primary lesions and 12 (32%) metastatic lymph nodes of 38 cases. In 70% of positive cases of primary lesions, the percentage of stained cells with MAGE-3 decreased in metastatic lymph nodes. The heterogeneous expression of MAGE-3 should be considered when we perform antigen specific immunotherapy for patients with gastric carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=0033190659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033190659&partnerID=8YFLogxK
M3 - Article
C2 - 10425289
AN - SCOPUS:0033190659
VL - 6
SP - 975
EP - 977
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 5
ER -